... CAMBRIDGE England November 10 /- ...- ( Stem Cell Sciences SCS the Company ) ...Stem Cell Sciences plc (AIM:STEM ASX:STC) a company focused on thec...CHDI and its collaborators have developed a unique series of 20 ES cel...

Stem Cell Sciences plc (AIM:STEM, ASX:STC), a company focused on the
commercialisation of stem cells and stem cell technologies, announces that
it has entered into an agreement with CHDI Foundation, Inc., to support the
standardisation of CHDI's novel mouse embryonic stem (ES) cell lines. CHDI
is a US non-profit organisation pursuing treatments for Huntington's
disease (HD). The cell lines have been produced over a period of several
years under varying conditions, and conversion to a standard methodology is
expected to facilitate their use in HD-related research towards the
development of new HD drugs and diagnostics.

CHDI and its collaborators have developed a unique series of 20 ES cell
lines from genetically modified mouse models that mimic aspects of
Huntington's disease. These cell lines and mouse models represent an
important tool for medical researchers to use in a wide variety of research
programmes in HD, a genetic neurological disorder affecting 7 in 100,000
people. High-quality mouse ES cells are expected to be important and
valuable for drug target validation and drug screening efforts.

Under the service agreement announced today, SCS will create standard
culture conditions for CHDI's mouse ES cell lines using its serum-free and
feeder-free ESGRO Complete(TM) media. Financial terms have not been
disclosed. Initially, SCS will convert three cell lines to the standardised
culture conditions and will monitor their viability and stability during
this process. If successful, the Company may have the opportunity to apply
its proprietary technologies across the entire range of CHDI's mouse ES
cell lines, as well as providing the Foundation and researchers with media
and reagents for future programmes.

"Switching these cell lines to ESGRO Complete(TM) media will allow
researchers around the world to apply uniform media and growth conditions
for easy maintenance of CHDI's mouse model ES cell lines, removing a
substantial source of experimental variability," said George Murphy, Senior
Vice President of SCS LLC. "The deal is a further validation of the quality
of SCS' media, and repeat use of CHDI's cell lines is expected to generate
further revenue growth from ESGRO Complete(TM)."

"The experience of Stem Cell Sciences in standardising conditions for
growing stem cells should help accelerate the evaluation of the various
mouse ES cells for HD target validation and drug discovery programs.
Working with SCS furthers CHDI's goal of making high quality reagents
available to the HD research community," said Dr Jamshid Arjomand, Director
of Basic Research at CHDI, overseeing the Foundation's stem cell
initiative.

ESGRO Complete(TM) and several other proprietary SCS media products are
distributed worldwide under an exclusive licence agreement with
Chemicon/Millipore Corporation.

About Stem Cell Sciences plc

Stem Cell Sciences (SCS) is an international research and development
company focusing on the commercial application of stem cell biology
technologies for drug discovery and regenerative medicine research. Stem
Cell Sciences is now focussing on building revenues through the sale of
products, collaborative research and licensing deals with international
biotechnology and pharmaceutical companies.

Stem Cell Sciences has a substantial portfolio of patents and patent
applications in both adult and embryonic stem cell fields. The Company has
been active in the stem cell research field since 1994, principally focused
on technologies to grow, differentiate, and purify adult and embryonic stem
cells. These include technologies to permit the generation of highly
purified stem cells and their differentiated progeny (specialised tissue
cell types) for use in genetic, pharmacological and toxicological screens.
Moreover, these technologies may be able to provide pure populations of
appropriate cell types for transplantation therapies in the future.

The Company has its main research base and headquarters in Cambridge,
UK with a second research base in Monash near Melbourne, Australia and a
business development office in San Francisco, USA.

Huntington's disease is a familial disease caused by a mutation in the
huntingtin gene. Each child of a parent with a mutation in the huntingtin
gene has a 50-50 chance of inheriting the mutation. As a result of carrying
the mutation, an individual's brain cells fail and die leading to cognitive
and physical impairments that, over the course of the disease,
significantly impair the individual's quality of life and ultimately causes
death. Symptoms of Huntington's disease, which generally develop in midlife
and become progressively more debilitating as time passes, can also develop
in infancy or old age. Once overt symptoms start, patients live for about
15 to 20 years. One person in 10,000 is believed to carry a mutation in the
huntingtin gene. There is currently no way to delay the onset of symptoms
or slow the progression of Huntington's disease.

About CHDI Foundation, Inc.

CHDI is a non-profit organization with a mission to rapidly discover
and develop drugs that delay or slow Huntington's disease. CHDI supports an
international network of research laboratories from academia and industry
pursuing novel therapies for the treatment of Huntington's disease. As a
collaborative enabler, CHDI seeks to bring the right partners together to
identify and address critical scientific issues and move drug candidates to
clinical evaluation as quickly as possible. More information about CHDI can
be found at http://www.chdifoundation.org.

(Date:12/8/2016)... AskLinkerReports.com has published a report on ... Industry 2016 Market Research Report. From a basic outline of ... are all covered in the report. This report projects investment ... of the Amyloglucosidase industry. ... , , Complete ...

(Date:11/29/2016)... , Nov. 29, 2016 BioDirection, a privately ... products for the objective detection of concussion and other ... has successfully completed a meeting with the U.S. Food ... blood test Pre-Submission Package. During the meeting company representatives ... as a precursor to commencement of a planned pilot ...

(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...

(Date:11/17/2016)... , Nov. 17, 2016 AIC announces that it has just released a new ... that require high-performance scale-out plus high speed data transfer storage solutions. Photo ... ... ... Setting up a high performance computing ...